REGULATION OF NFKB IN LUNG EPITHELIUM BY ROS/RNS

ROS/RNS 对肺上皮中 NFKB 的调控

基本信息

项目摘要

The interaction of reactive nitrogen species (ROS/RNS) with lung epithelium, the first cell in contact with inhaled toxicants, may be critical in the initiation of pulmonary disease. Activation of signalling cascades and transcription factors may be important in determining the phenotypic outcome of exposure to these reactive metabolites and the activation of an inflammatory response. In this proposal we focus on the transcription factor, nuclear factor kappa B (Nf-kappaB) in a rat alveolar type II epithelial cell line (RLE) exposed to ROS or RNS. We hypothesize that activation of NF-kappaB by critical ROS/RNS occurs through unique signalling pathways that include mitogen- activated protein kinases (MAPK) and tyrosine kinases, and that the balance of these events is pivotal in the initiation of lung injury. NF-kappaB is critical in the regulation of genes with multiple functions that are involved in inflammation, immune immodulation or survival. Prevention of apoptosis by NF-kappaB may lead to activation of inflammatory genes, a hallmark of oxidant lung injury. Due to its' complex functions, the phenotypic implications of NF-kappaB activation in lung epithelium are obscure to date. In this proposal, we seek to investigate the mechanisms by which ROS or RNS activate NF-kappaB, the critical signalling pathways and the functional implications of NF- kappaB activation in RLE cells. We will investigate two critical RNS, hydrogen peroxide, or peroxynitrite to determine the implications of NF- kappaB activation and phenotypic endpoints (apoptosis and expression of inflammatory genes).Modulation of NF-kappaB by overexpression or prevention of its activation will allow us to determine the implications of NF-kappaB activation in lung epithelium by ROS and RNS. Furthermore, assessment of upstream signalling cascades and MAPKs as well as the modulation of various MAPKs will elucidate the critical signalling pathways by which ROS/RNS induce NF-kappaB. Combined approaches in specific aims 1-4 will lead to a better understanding of the role of NF- kappaB in pulmonary disease associated with exposure to ROS/RNS and may provide strategies for therapeutic intervention.
活性氮(ROS/RNS)与肺组织的相互作用 上皮细胞是与吸入毒物接触的第一个细胞,可能是 在肺部疾病的发生中起关键作用。 激活 信号级联和转录因子可能是重要的 确定暴露于这些反应性物质的表型结果, 代谢物和炎症反应的激活。 在这 建议我们重点研究转录因子核因子κ B (NF-κ B)在大鼠肺泡II型上皮细胞系(RLE)中暴露于 ROS或RNS。 我们假设,NF-κ B的激活是由关键的 ROS/RNS通过独特的信号通路发生,包括促分裂原- 活化蛋白激酶(MAPK)和酪氨酸激酶, 这些事件的平衡在肺损伤的起始中是关键的。 NF-kappaB在多功能基因调控中起关键作用 参与炎症、免疫失调或生存。 通过NF-κ B阻止细胞凋亡可能会导致 炎症基因,氧化性肺损伤的标志。 由于其“ 复杂的功能,NF-κ B活化的表型意义 迄今为止,肺上皮细胞中存在的问题尚不清楚。 在本建议中,我们力求 研究ROS或RNS激活NF-κ B的机制, 关键信号通路和NF-的功能意义 RLE细胞中的kappaB活化。我们将调查两个关键的RNS, 过氧化氢,或过氧亚硝酸盐,以确定NF- kappaB活化和表型终点(细胞凋亡和 通过过度表达或过度表达调节NF-κ B, 阻止它的激活将使我们能够确定 ROS和RNS对肺上皮细胞NF-κ B活化的影响。此外,委员会认为, 上游信号级联和MAPK的评估以及 各种MAPKs的调节将阐明关键的信号传导 ROS/RNS诱导NF-κ B的途径。 综合办法, 具体目标1-4将导致更好地理解NF的作用, kappaB在与暴露于ROS/RNS相关的肺部疾病中的作用, 提供治疗干预的策略。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(3)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Yvonne M. W. Janssen-Heininger其他文献

Small molecule-mediated inhibition of the oxidoreductase ERO1A restrains aggressive breast cancer by impairing VEGF and PD-L1 in the tumor microenvironment
小分子介导的氧化还原酶 ERO1A 的抑制通过损害肿瘤微环境中的血管内皮生长因子和程序性死亡配体 1 来抑制侵袭性乳腺癌
  • DOI:
    10.1038/s41419-025-07426-1
  • 发表时间:
    2025-02-17
  • 期刊:
  • 影响因子:
    9.600
  • 作者:
    Ersilia Varone;Michele Retini;Alessandro Cherubini;Alexander Chernorudskiy;Alice Marrazza;Andrea Guidarelli;Alfredo Cagnotto;Marten Beeg;Marco Gobbi;Stefano Fumagalli;Marco Bolis;Luca Guarrera;Maria Chiara Barbera;Chiara Grasselli;Augusto Bleve;Daniele Generali;Manuela Milani;Michele Mari;Mario Salmona;Giovanni Piersanti;Giovanni Bottegoni;Massimo Broggini;Yvonne M. W. Janssen-Heininger;Jaehyung Cho;Orazio Cantoni;Ester Zito
  • 通讯作者:
    Ester Zito

Yvonne M. W. Janssen-Heininger的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Yvonne M. W. Janssen-Heininger', 18)}}的其他基金

Glutaredoxin, Glutathione Metabolism and Lung Cancer
谷氧还蛋白、谷胱甘肽代谢与肺癌
  • 批准号:
    10657945
  • 财政年份:
    2023
  • 资助金额:
    $ 23.61万
  • 项目类别:
Collagen Oxidation, Myofibroblast Activation and Age-Associated Pulmonary Fibrosis
胶原蛋白氧化、肌成纤维细胞激活和年龄相关性肺纤维化
  • 批准号:
    10532853
  • 财政年份:
    2022
  • 资助金额:
    $ 23.61万
  • 项目类别:
Collagen Oxidation, Myofibroblast Activation and Age-Associated Pulmonary Fibrosis
胶原蛋白氧化、肌成纤维细胞激活和年龄相关性肺纤维化
  • 批准号:
    10445737
  • 财政年份:
    2021
  • 资助金额:
    $ 23.61万
  • 项目类别:
2020 Oxygen Radicals Gordon Research Conference (GRC) and Gordon Research Seminar (GRS)
2020年氧自由基戈登研究会议(GRC)和戈登研究研讨会(GRS)
  • 批准号:
    9912443
  • 财政年份:
    2020
  • 资助金额:
    $ 23.61万
  • 项目类别:
S-glutathionylation chemistry in fibrotic lung remodeling
纤维化肺重塑中的 S-谷胱甘肽化学
  • 批准号:
    10585922
  • 财政年份:
    2017
  • 资助金额:
    $ 23.61万
  • 项目类别:
S-glutathionylation chemistry in fibrotic lung remodeling
纤维化肺重塑中的 S-谷胱甘肽化学
  • 批准号:
    10320789
  • 财政年份:
    2017
  • 资助金额:
    $ 23.61万
  • 项目类别:
Redox-based Fas signaling in allergic airway disease
过敏性气道疾病中基于氧化还原的 Fas 信号传导
  • 批准号:
    7822474
  • 财政年份:
    2009
  • 资助金额:
    $ 23.61万
  • 项目类别:
Epithelial JNK-TGFb1 Signaling Axis in Airway Remodeling
气道重塑中的上皮 JNK-TGFb1 信号轴
  • 批准号:
    7367482
  • 财政年份:
    2008
  • 资助金额:
    $ 23.61万
  • 项目类别:
Epithelial JNK-TGFb1 Signaling Axis in Airway Remodeling
气道重塑中的上皮 JNK-TGFb1 信号轴
  • 批准号:
    7644952
  • 财政年份:
    2008
  • 资助金额:
    $ 23.61万
  • 项目类别:
Redox Biology in COPD
慢性阻塞性肺病中的氧化还原生物学
  • 批准号:
    7690866
  • 财政年份:
    2008
  • 资助金额:
    $ 23.61万
  • 项目类别:

相似海外基金

Establishment of a Mouse NK Cell Line for Analyzing Tumor Infiltration Processes and Developing a Preclinical Model for Cancer Immunotherapy.
建立小鼠 NK 细胞系,用于分析肿瘤浸润过程并开发癌症免疫治疗的临床前模型。
  • 批准号:
    23K06731
  • 财政年份:
    2023
  • 资助金额:
    $ 23.61万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Proof of usefulness of PDX derived cell line
PDX 衍生细胞系的有用性证明
  • 批准号:
    23K06616
  • 财政年份:
    2023
  • 资助金额:
    $ 23.61万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A novel producer cell line for more efficient manufacturing of viral vector systems
用于更有效地制造病毒载体系统的新型生产细胞系
  • 批准号:
    10597799
  • 财政年份:
    2023
  • 资助金额:
    $ 23.61万
  • 项目类别:
Genestorian: a web application to document and trace genetic modifications in model organism and cell line collections.
Genestorian:一个网络应用程序,用于记录和追踪模型生物和细胞系集合中的遗传修饰。
  • 批准号:
    EP/Y024591/1
  • 财政年份:
    2023
  • 资助金额:
    $ 23.61万
  • 项目类别:
    Fellowship
AI-Aided Tool for Day Zero Selection of High Performing Cells for Biopharma Cell Line Development
用于生物制药细胞系开发的高性能细胞零日选择的人工智能辅助工具
  • 批准号:
    10672364
  • 财政年份:
    2022
  • 资助金额:
    $ 23.61万
  • 项目类别:
Developing a stable cell line expressing recombinant sclerostin
开发表达重组硬化素的稳定细胞系
  • 批准号:
    10385037
  • 财政年份:
    2022
  • 资助金额:
    $ 23.61万
  • 项目类别:
Development of Natural Killer (NK) Cell Line-Derived Extracellular Vesicles as a New Treatment for Cancer
开发自然杀伤 (NK) 细胞系衍生的细胞外囊泡作为癌症的新治疗方法
  • 批准号:
    10383462
  • 财政年份:
    2022
  • 资助金额:
    $ 23.61万
  • 项目类别:
A cell culture management platform to improve biomedical reproducibility by combining cell line tracking, low-cost genetic analysis, and riskassessment
细胞培养管理平台,通过结合细胞系追踪、低成本遗传分析和风险评估来提高生物医学重现性
  • 批准号:
    10483063
  • 财政年份:
    2022
  • 资助金额:
    $ 23.61万
  • 项目类别:
AI-Aided Tool for Day Zero Selection of High Performing Cells for Biopharma Cell Line Development
用于生物制药细胞系开发的高性能细胞零日选择的人工智能辅助工具
  • 批准号:
    10546865
  • 财政年份:
    2022
  • 资助金额:
    $ 23.61万
  • 项目类别:
Modulating expression of candidate genes to improve lentiviral vector production in stable cell line
调节候选基因的表达以提高稳定细胞系中慢病毒载体的产量
  • 批准号:
    2752732
  • 财政年份:
    2022
  • 资助金额:
    $ 23.61万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了